Clinical Trial

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-24; most recent amendment 2026-01-18.
Status change: Not Yet Recruiting → Recruiting 2025-02-21
Trial Details
NCT Number NCT06430437
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Non-Small Cell Lung Cancer With HER2- Mutations
Enrollment 300 participants
Start Date 2024-07-29
Primary Completion 2026-02 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-21